SoftBank Results Presentation Deck
SVF2
PROGRESS & HIGHLIGHTS
A Broad and Diverse Portfolio...
As of March 31, 2021
SVF2
Launch
OCT. 2019
44
Total Number of Portfolio
Companies¹
$6.2B
Total Invested²
PRIVATE3
Encoded
THERAPEUTICS
KARIUS
biofourmis
PEAR
THERAPEUTICS
ShipBob
етого»
PUBLIC4
DiDi Autonomous WHOOP
贝壳
Mind Tickle
BEIKE
M
MEMPHIS
MEATS
TESSERA
Ordermark.
STANDARD
XXtalPi
掌门教育
zhangmen.com
seer
unacademy
TEMPO
VIVIDION
Therapeutics
*cameo
MANTICORE redislabs
GAMES
qualtrics.XM
alto
lenskart.com
BEHAVOX
// FORWARD
elevatebio
sendbird
Full Truck Alliance
The Investments presented herein are solely for illustrative purposes, have been selected in order to demonstrate examples of SoftBank Vision Fund 2 Investments, and do not purport to be a complete list thereof. References to individual Investments should not be construed as a recommendation of any specific Investment or security.
Please refer to visionfund.com/portfolio for a more complete list of SoftBank Vision Fund 2 Investments.
M
ED
TIER
BG
K
keep
EDA
Technology
BERKSHIRE
GREY
patsnap
Undisclosed
jobandtalent Company (3x)
ΤΗΙΝΚ
.? 就百思维
孩子爱上的数学课
FF Flock Freight
XAG
WER CUTE CHAT
Klarna.
Footnotes:
1. Total Number of Portfolio Companies include investments in portfolio companies made by the Fund and joint-ventures with existing portfolio companies from the Fund's inception to March 31, 2021. Total excludes minor equity stakes in companies received through existing Fund investments.
2. Total Invested includes all capital invested in companies by SoftBank Vision Fund 2 from Fund inception to March 31, 2021.
3. Private is the total number of SoftBank Vision Fund 2 portfolio company Investments that have not been fully Realized or publicly listed as of March 31, 2021. Private Portfolio company logos exclude minor equity stakes in companies received through existing Fund investments and any undisclosed investments.
4. Public includes publicly listed portfolio companies that SoftBank Vision Fund 2 has not fully exited as of March 31, 2021.
=SoftBank
Investment AdvisersView entire presentation